Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
China SXT Pharmaceuticals Inc (SXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.76% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price - |
Price to earnings Ratio 0.01 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 |
52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 124.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 318.69% | Operating Margin (TTM) -76.95% |
Management Effectiveness
Return on Assets (TTM) 18.15% | Return on Equity (TTM) 57.63% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 190144853 | Price to Sales(TTM) 109.75 |
Enterprise Value 190144853 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 104.57 | Enterprise Value to EBITDA 29.92 | Shares Outstanding 116028000 | Shares Floating 488309 |
Shares Outstanding 116028000 | Shares Floating 488309 | ||
Percent Insiders 0.02 | Percent Institutions 0.01 |
Upturn AI SWOT
China SXT Pharmaceuticals Inc
Company Overview
History and Background
China SXT Pharmaceuticals Inc., founded in 2005, is engaged in the research, development, manufacture, marketing, and sales of traditional Chinese medicine (TCM) products, particularly concentrated TCM granules. It has focused on modernizing TCM production.
Core Business Areas
- TCM Granules: Development, manufacturing, and sales of concentrated TCM granules. These are small, easily dissolved forms of traditional Chinese medicine, offering convenience.
- TCM Powder: Traditional Chinese medicine in powder form, offering a similar benefit to TCM granules.
- Advanced Technology TCM Products: Traditional Chinese medicine products that incorporates advance technology.
- Other TCM Products: Production and sales of other TCM products, including raw herbs.
Leadership and Structure
The company has a board of directors and executive management team overseeing its operations. The structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- TCM Granules: Concentrated TCM granules are their primary product. Market share data is not publicly available. Competitors are other TCM manufacturers in China; these do not have US stock listings.
- TCM Powder: Traditional Chinese medicine in powder form, offering a similar benefit to TCM granules. Market share data is not publicly available. Competitors are other TCM manufacturers in China; these do not have US stock listings.
Market Dynamics
Industry Overview
The TCM market in China is large and growing, driven by increasing demand for natural and traditional healthcare solutions.
Positioning
China SXT Pharmaceuticals Inc. aims to be a modern TCM manufacturer, focusing on standardized production and quality control. They compete with other TCM manufacturers.
Total Addressable Market (TAM)
The TCM market in China is estimated to be worth billions of dollars. China SXT Pharmaceuticals Inc. aims to capture a significant share through its product offerings.
Upturn SWOT Analysis
Strengths
- Focus on TCM granules
- Modernized production facilities
- Experienced management team
Weaknesses
- Limited brand recognition
- Concentration in a single market
- Reliance on a few key products
Opportunities
- Expansion into new markets
- Development of new TCM products
- Strategic partnerships
- Increased demand for TCM
Threats
- Competition from other TCM manufacturers
- Changes in regulations
- Price pressures
- Economic downturn
Competitors and Market Share
Key Competitors
Competitive Landscape
China SXT Pharmaceuticals Inc. competes with numerous TCM manufacturers in China. However, a direct market share comparison is difficult due to the fragmentation of the Chinese TCM market.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent and subject to market conditions.
Future Projections: Future projections are uncertain and dependent on market conditions and company performance.
Recent Initiatives: Recent initiatives focused on expanding sales and product development.
Summary
China SXT Pharmaceuticals Inc. is a TCM manufacturer focusing on granules, but its financial performance is volatile. The company faces competition in the Chinese market and needs to expand its brand and product offerings. Investment is speculative due to inconsistently reported financials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and may not be complete. Investment decisions should be based on thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China SXT Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-01-04 | Chairman of the Board & Co-CEO Mr. Feng Zhou | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 75 | Website https://www.sxtchina.com |
Full time employees 75 | Website https://www.sxtchina.com | ||
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.